Dorsey Wright & Associates’s Ascendis Pharma A/S ASND Stock Holding History

Dorsey Wright & Associates’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.25M	Sell	8,427 -3,452	-29%	-$806K	0.38%	69
2026 Q1	$2.72M	Buy	11,879 +3,375	+40%	+$757K	0.34%	73
2025 Q4	$1.81M	Buy	8,504 +263	+3%	+$54.3K	0.39%	78
2025 Q3	$1.64M	Sell	8,241 -1,031	-11%	-$192K	0.37%	78
2025 Q2	$1.6M	Buy	+9,272	New	+$1.51M	0.38%	86

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Dorsey Wright & Associates's ASND Position: Q2 2026 in Review

Dorsey Wright & Associates reduced its Ascendis Pharma A/S (ASND) stake by 29% in Q2 2026, selling an estimated $806K and leaving 8,427 shares worth $2.25M. The position accounts for 0.38% of the portfolio, ranked #69.

Dorsey Wright & Associates first reported a position in ASND in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.72M in Q1 2026. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Dorsey Wright & Associates held 8,427 shares of Ascendis Pharma A/S worth $2.25M as of Q2 2026.
Dorsey Wright & Associates sold 3,452 Ascendis Pharma A/S shares in Q2 2026, an estimated $806K.
Ascendis Pharma A/S made up 0.38% of Dorsey Wright & Associates's portfolio in Q2 2026, its #69 holding.
Dorsey Wright & Associates first reported a position in Ascendis Pharma A/S in Q2 2025 and has held it in 5 quarters since.
Dorsey Wright & Associates's Ascendis Pharma A/S position peaked at $2.72M in Q1 2026.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Dorsey Wright & Associates's 13F filing for Q2 2026, filed 6 Aug 2026.